Literature DB >> 9429743

Effects of glycosylation of hypoglycaemic drug binding to serum albumin.

H Koyama1, N Sugioka, A Uno, S Mori, K Nakajima.   

Abstract

The binding properties of hypoglycaemic drugs to glycosylated human serum albumin (G-HSA) were investigated using a fluorescence quenching method. Displacement patterns between tolbutamide and Sudlow's-site-specific drugs to G-HSA were also investigated. The order of the binding affinities of these drugs to HSA was glibenclamide > acetohexamide > tolbutamide > or = glicrazide > metfolmin. The order of the binding affinities were the same for G-HSA as for HSA. The ability of G-HSA to bind hypoglycaemic drugs, however, was much lower than that of HSA. Scatchard plots for the binding of tolbutamide to both albumins were biphasic. The glycosylation affected saturable binding sites (I and II), whereas it did not influence non-saturable binding sites. The displacement patterns of tolbutamide binding between both albumins were not affected in the presence of site-I- or III-specific drugs, whereas the relative binding of tolbutamide to site-II-specific drugs between the two albumins was remarkably changed. The glycosylation of HSA not only increases the unbound drug concentration but also changes the displacement pattern at site II. Our results suggest that the extensive glycosylation of plasma proteins in diabetic patients complicates drug-drug interactions beyond those seen in normal people.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429743     DOI: 10.1002/(sici)1099-081x(199712)18:9<791::aid-bdd66>3.0.co;2-1

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  19 in total

1.  The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan.

Authors:  K S Joseph; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2010-05-06       Impact factor: 3.935

2.  Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.

Authors:  K S Joseph; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-06-01       Impact factor: 3.205

3.  Comparison of modification sites formed on human serum albumin at various stages of glycation.

Authors:  Omar S Barnaby; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-10-27       Impact factor: 3.786

4.  Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids.

Authors:  Sara B G Basiaga; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-23       Impact factor: 3.205

5.  Use of entrapment and high-performance affinity chromatography to compare the binding of drugs and site-specific probes with normal and glycated human serum albumin.

Authors:  Abby J Jackson; Jeanethe Anguizola; Erika L Pfaunmiller; David S Hage
Journal:  Anal Bioanal Chem       Date:  2013-05-09       Impact factor: 4.142

6.  Analysis of multi-site drug-protein interactions by high-performance affinity chromatography: Binding by glimepiride to normal or glycated human serum albumin.

Authors:  Ryan Matsuda; Zhao Li; Xiwei Zheng; David S Hage
Journal:  J Chromatogr A       Date:  2015-07-06       Impact factor: 4.759

7.  Perinatal growth restriction decreases diuretic action of furosemide in adult rats.

Authors:  Barent N DuBois; Jacob Pearson; Tahir Mahmood; Duc Nguyen; Kent Thornburg; Ganesh Cherala
Journal:  Eur J Pharmacol       Date:  2014-02-05       Impact factor: 4.432

8.  Quantitative analysis of glycation sites on human serum albumin using (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Omar S Barnaby; Chunling Wa; Ronald L Cerny; William Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2010-04-13       Impact factor: 3.786

9.  Analysis of drug-protein binding using on-line immunoextraction and high-performance affinity microcolumns: Studies with normal and glycated human serum albumin.

Authors:  Ryan Matsuda; Donald Jobe; Jared Beyersdorf; David S Hage
Journal:  J Chromatogr A       Date:  2015-09-09       Impact factor: 4.759

10.  Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin.

Authors:  Ryan Matsuda; Jeanethe Anguizola; K S Joseph; David S Hage
Journal:  J Chromatogr A       Date:  2012-10-08       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.